Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Abilify cases. Here at Leading Justice, we can custom-tailor your firm’s Abilify advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Abilify advertising, plus a fee for every case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using innovative approaches to target contacts specifically related to Abilify use and side effects like pathological gambling, binge eating and compulsive behavior, Leading Justice will increase your firm’s Abilify caseload. If you are interested in helping victims of alleged Abilify side effects, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence to allocate your full budget and rest easy knowing your money is being spent in the best way possible.
Each and every law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will customize our Abilify case intake specifications to the exact criteria you are seeking. So, if your firm has specific Abilify qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Abilify data with no chance of fraud.
Abilify Side Effect Litigation
The atypical antipsychotic Abilify (aripiprazole) is one of the best-selling medications in the world, bringing in approximately $6.8 billion in sales for Bristol-Myers Squibb and Otsuka Pharmaceutical Company each year. Close to one million Americans are prescribed Abilify annually for mental health disorders ranging from major depression to schizophrenia and bipolar disorder, and the drug can be effective in managing the symptoms of these conditions. Unfortunately, what many people don’t know, is that Abilify has also been linked to an increased risk of unexpected compulsive behaviors in users, including pathological gambling, hypersexuality and binge eating. Plaintiffs involved in the ongoing Abilify litigation have argued that these side effects constitute a physical injury, due to the potential for the compulsive behaviors to cause significant financial harm and overall ruin.
In some instances of compulsive gambling side effects from Abilify, the urge to gamble is so strong, the individual will continue to gamble even when he or she can’t afford it, gambling with credit cards or borrowed money, which can lead to exorbitant gambling debts, psychological distress and financial ruin. A number of Abilify lawsuits have already been brought against Ostuka Pharmaceutical Company and Bristol-Myers Squibb, alleging that the drug makers’ antipsychotic drug caused them to develop a compulsive gambling habit that cost them tens of thousands of dollars in gambling losses. As more and more former Abilify users become aware of the potential for the antipsychotic drug to cause pathological gambling, overeating, hypersexuality and other compulsive behaviors, additional Abilify lawsuits are expected to be filed in the future.
